NCT02848170View on ClinicalTrials.gov

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Essential Hypertension
Interventions
DRUG

CS-3150

CS-3150 2.5mg, oral

DRUG

olmesartan medoxomil

olmesartan medoxomil 10 mg, oral

Trial Locations (1)

Unknown

Tokyo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY